Sign inJoin waitlistJoin the waitlist

Christine Alewine

Associate Professor of Medicine · Geisel School of Medicine

Credentials: · · · · · ·

History

Geisel School of Medicine
Present

Hematology and Medical Oncology
Clinical Center at the National Institutes of Health
2011–2014
Pathology
National Institutes of Health
2008–2011
Dartmouth Cancer Center
2008–2011
University of Maryland School of Medicine
2004–2008
Dartmouth College
1994–1998

Research

Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Review · Journal of Clinical Oncology · 2016 · 292 citations
Advances in anticancer immunotoxin therapy
Review · The Oncologist · 2015 · First of 3 authors · 150 citations
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
Journal of Clinical Oncology · 2018 · 150 citations

AT
Anish Thomas
7 papers
NS
Nebojša Skorupan
6 papers · 3 as a fellow
William Figg
5 papers
Michael Rudloff
4 papers · 1 as a resident
Brendan Hagerty
3 papers · 3 as a fellow
GP
Guillaume Pegna
3 papers · 1 as a fellow
IM
Idrees Mian
3 papers · 3 as a fellow
Markku Miettinen
3 papers
RF
Rebekah Felicelli
3 papers · 1 as a resident
Amber Gallanis
2 papers · 2 as a fellow
Andrew Blakely
2 papers
Arun Rajan
2 papers

Grants

Precision Therapy to Target Pancreatic Ductal Adenocarcinoma
National Cancer Institute · ZIA
Contact PI · $7.9M · Division of Basic Sciences - Nci
First in Human Trials of ProAgio, a Cytotoxin
National Cancer Institute · ZIA
Contact PI · $3.7M · Division of Basic Sciences - Nci
Rare Exocrine Tumors of the Pancreas
National Cancer Institute · ZIA
Contact PI · $1.3M · Division of Basic Sciences - Nci
Clinical Support
National Cancer Institute · ZIE
Contact PI · $217.5K · Division of Basic Sciences - Nci

Clinical trials

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)
2019–2021
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Principal investigator · Completed · Phase 1, Phase 2
National Cancer Institute (NCI)
2016–2021